Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2015-04-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1535-7163.MCT-15-0028PMID 25931518PMCID PMC4497872
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The phosphoinositide 3-kinase pathway and therapy resistance in cancer

  2015cited by this paper
• Discovery and characterization of small molecules that target the GTPase Ral

  2014cited by this paper
• Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK

  2014cited by this paper
• Cdk5-mediated phosphorylation of RapGEF2 controls neuronal migration in the developing cerebral cortex

  2014cited by this paper
• Use of statins and the risk of death in patients with prostate cancer.

  2014cited by this paper
• MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis

  2014cited by this paper
• Dragging ras back in the ring.

  2014cited by this paper
• Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer

  2014cited by this paper
• Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor.

  2014cited by this paper
• Epigenetic silencing of EYA2 in pancreatic adenocarcinomas promotes tumor growth

  2014cited by this paper
• Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange

  2014cited by this paper
• Safety/efficacy of MK-8669 (ridaforolimus) plus MK-2206 (AKT inhibitor) in patients with advanced breast cancer with low RAS signature and PTEN deficient prostate cancer.

  2014cited by this paper
• Cancer statistics, 2014

  2014cited by this paper
• Synergistic Effects of Concurrent Blockade of PI3K and MEK Pathways in Pancreatic Cancer Preclinical Models

  2013cited by this paper
• Roles for KRAS in pancreatic tumor development and progression.

  2013cited by this paper
• EGFR/MEK/ERK/CDK5-dependent integrin-independent FAK phosphorylated on serine 732 contributes to microtubule depolymerization and mitosis in tumor cells

  2013cited by this paper
• Cyclin-dependent kinase inhibitors closer to market launch?

  2013cited by this paper
• Faculty Opinions recommendation of K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.

  2013cited by this paper
• Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling

  2013cited by this paper
• K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

  2013cited by this paper
• The role of Cdk5 in neuroendocrine thyroid cancer.

  2013cited by this paper
• Cyclin-dependent kinase 5 modulates STAT3 and androgen receptor activation through phosphorylation of Ser⁷²⁷ on STAT3 in prostate cancer cells.

  2013cited by this paper
• Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

  2013cited by this paper
• Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells.

  2013cited by this paper
• K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo

  2012cited by this paper
• Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity

  2012cited by this paper
• Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice.

  2012influential reference
• Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck

  2012cited by this paper
• Twice switched at birth: cell cycle-independent roles of the "neuron-specific" cyclin-dependent kinase 5 (Cdk5) in non-neuronal cells.

  2011cited by this paper
• First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.

  2011cited by this paper
• A Polymeric Nanoparticle Encapsulated Small-Molecule Inhibitor of Hedgehog Signaling (NanoHHI) Bypasses Secondary Mutational Resistance to Smoothened Antagonists

  2011cited by this paper
• Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models

  2011influential reference
• Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

  2010cited by this paper
• Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling.

  2010influential reference
• MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

  2010cited by this paper
• The proapoptotic function of Noxa in human leukemia cells is regulated by the kinase Cdk5 and by glucose.

  2010cited by this paper
• Systemic Administration of Polymeric Nanoparticle-Encapsulated Curcumin (NanoCurc) Blocks Tumor Growth and Metastases in Preclinical Models of Pancreatic Cancer

  2010cited by this paper
• CYCLIN DEPENDENT KINASE 5 (CDK5) REGULATES ENDOTHELIAL CELL MIGRATION AND ANGIOGENESIS

  2010cited by this paper
• Cyclin-dependent Kinase 5 Regulates Endothelial Cell Migration and Angiogenesis

  2010cited by this paper
• Abstract #DDT01-1: MK-2206: A potent oral allosteric AKT inhibitor

  2009cited by this paper
• Talin Phosphorylation by Cdk5 regulates Smurf1-mediated talin head ubiquitination and cell migration

  2009cited by this paper
• Cdk5-mediated regulation of the PIKE-A-Akt pathway and glioblastoma cell invasion

  2008cited by this paper
• Cyclin-Dependent Kinase 5 Supports Neuronal Survival through Phosphorylation of Bcl-2

  2008cited by this paper
• Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

  2008influential reference
• Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers.

  2007cited by this paper
• High-content screening.

  2007cited by this paper
• ImageJ for microscopy.

  2007cited by this paper
• Cdk5 Regulates STAT3 Activation and Cell Proliferation in Medullary Thyroid Carcinoma Cells*

  2007cited by this paper
• AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.

  2006cited by this paper
• Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells.

  2006cited by this paper
• Extraneuronal roles of cyclin‐dependent kinase 5

  2006cited by this paper
• Cyclin-dependent kinase pathways as targets for cancer treatment.

  2006cited by this paper
• Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells.

  2006cited by this paper
• An In vivo Platform for Translational Drug Development in Pancreatic Cancer

  2006influential reference
• Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance.

  2005cited by this paper
• Cyclin-dependent kinase 5 phosphorylates signal transducer and activator of transcription 3 and regulates its transcriptional activity.

  2004cited by this paper
• Serine 732 phosphorylation of FAK by Cdk5 is important for microtubule organization, nuclear movement, and neuronal migration.

  2003cited by this paper
• Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

  2003influential reference
• Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.

  2003influential reference
• Distinct requirements for Ras oncogenesis in human versus mouse cells.

  2002cited by this paper
• Life is a journey: a genetic look at neocortical development

  2002cited by this paper
• Cancer statistics

  1989cited by this paper
• Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes.

  1988cited by this paper
• KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas.

  1988cited by this paper

• Roles of CDK12/CDK13 and development of inhibitors and degraders.

  2026cites this paper
• Novel selective strategies targeting the BCL-2 family to enhance clinical efficacy in ALK-rearranged non-small cell lung cancer

  2025cites this paper
• Grandifloridin D: A Potent Antiausterity Agent Targeting Pancreatic Cancer Cells via Akt/mTOR and Autophagy Inhibition.

  2025cites this paper
• Targeting CDKs in cancer therapy: advances in PROTACs and molecular glues

  2025cites this paper
• Genomic instability, DNA damage response and telomere homeostasis in pancreatic cancer.

  2025cites this paper
• PIK Your Poison: The Effects of Combining PI3K and CDK Inhibitors against Metastatic Cutaneous Squamous Cell Carcinoma In Vitro

  2024cites this paper
• Inhibition of the PI3K/AKT/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor?

  2024cites this paper
• The trend toward more target therapy in pancreatic ductal adenocarcinoma

  2024cites this paper
• Clinical and Preclinical Targeting of Oncogenic Pathways in PDAC: Targeted Therapeutic Approaches for the Deadliest Cancer

  2024cites this paper
• Recent advances in drug delivery and targeting for the treatment of pancreatic cancer.

  2024cites this paper
• The KRAS signaling pathway's impact on the characteristics of pancreatic cancer cells.

  2023cites this paper
• Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review)

  2023influential citation
• Targeting CDK1 in cancer: mechanisms and implications

  2023cites this paper
• Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal cell carcinoma

  2022cites this paper
• Estimating Metastatic Risk of Pancreatic Ductal Adenocarcinoma at Single-Cell Resolution

  2022cites this paper
• Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma

  2022cites this paper
• A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas

  2022cites this paper
• Targeting PI3K/AKT/mTOR Signaling Pathway in Pancreatic Cancer: From Molecular to Clinical Aspects

  2022cites this paper
• Current progress and novel strategies that target CDK12 for drug discovery.

  2022cites this paper
• The RAL Enigma: Distinct Roles of RALA and RALB in Cancer

  2022cites this paper
• Moving towards dawn: KRas signaling and treatment in pancreatic ductal adenocarcinoma.

  2022cites this paper
• Targeted therapy for pancreatic cancer: lessons learned and future opportunities

  2021cites this paper
• Targeting PI3K Pathway in Pancreatic Ductal Adenocarcinoma: Rationale and Progress

  2021cites this paper
• CDK5 positively regulates Notch1 signaling in pancreatic cancer cells by phosphorylation

  2021cites this paper
• CDK12: a potential therapeutic target in cancer.

  2020cites this paper
• Cell cycle regulators in cancer cell metabolism.

  2020cites this paper
• Dinaciclib prolongs survival in the LSL-KrasG12D/+ ; LSL-Trp53R172H/+ ; Pdx-1-Cre (KPC) transgenic murine models of pancreatic ductal adenocarcinoma.

  2020influential citation
• Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib

  2020cites this paper
• Prediction of therapeutic outcome and survival in a transgenic mouse model of pancreatic ductal adenocarcinoma treated with dendritic cell vaccination or CDK inhibitor using MRI texture: a feasibility study.

  2020cites this paper
• Discovery of Novel Turn-On Fluorescent Probes for Detecting PDEδ Protein in Living Cells and Tumor Slices.

  2020cites this paper
• A Phase I Study of Dinaciclib in Combination With MK‐2206 in Patients With Advanced Pancreatic Cancer

  2020cites this paper
• Light‐emitting diode irradiation induces AKT/mTOR‐mediated apoptosis in human pancreatic cancer cells and xenograft mouse model

  2020cites this paper
• Clinical and Pre-Clinical Evidence of Carbonic Anhydrase IX in Pancreatic Cancer and Its High Expression in Pre-Cancerous Lesions

  2020cites this paper
• PES1 promotes BET inhibitors resistance and cells proliferation through increasing c-Myc expression in pancreatic cancer

  2019cites this paper
• Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression

  2019cites this paper
• An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer

  2019cites this paper
• Local hyperthyroidism promotes pancreatic acinar cell proliferation during acute pancreatitis

  2019cites this paper
• Systematic Review of Patient-Derived Xenograft Models for Preclinical Studies of Anti-Cancer Drugs in Solid Tumors

  2019cites this paper
• KRAS: A promising therapeutic target for cancer treatment.

  2019cites this paper
• Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics

  2018cites this paper
• Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine

  2018cites this paper
• A genome-wide Drosophila epithelial tumorigenesis screen identifies Tetraspanin 29Fb as an evolutionarily conserved suppressor of Ras-driven cancer

  2018cites this paper
• The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma

  2018cites this paper
• Anti-tumor effect of CDK inhibitors on CDKN2A-defective squamous cell lung cancer cells

  2018cites this paper
• Combination of PI3K/Akt Pathway Inhibition and Plk1 Depletion Can Enhance Chemosensitivity to Gemcitabine in Pancreatic Carcinoma

  2018cites this paper
• A microfluidics platform for combinatorial drug screening on cancer biopsies

  2018cites this paper
• Perturbing anti-apoptotic proteins to develop novel cancer therapies

  2017cites this paper
• Inhibition of Cdk5 induces cell death of tumor-initiating cells

  2017cites this paper
• Cell cycle proteins as promising targets in cancer therapy

  2017cites this paper
• Synergistic antitumor effects of CDK inhibitor SNS-032 and an oncolytic adenovirus co-expressing TRAIL and Smac in pancreatic cancer

  2017cites this paper
• Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer

  2017cites this paper
• Targeting ClpXP protease-Interfering with mitochondrial proteostasis as anti-cancer strategy

  2017cites this paper
• Effect of Akti-2 on sperm motility, capacitation and acrosome reaction in a mouse model.

  2016cites this paper
• Targeting TGF-β1 and AKT signal on growth and metastasis of anaplastic thyroid cancer cell in vivo.

  2016cites this paper
• Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy

  2016cites this paper
• Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition

  2016cites this paper
• Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents.

  2016cites this paper
• KRAS-related proteins in pancreatic cancer.

  2016cites this paper
• HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy.

  2016cites this paper
• Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.

  2016cites this paper
• Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity

  2016cites this paper
• Cyclin E1 as a Therapeutic Target in Women with High Grade Serous Ovarian Cancer and Primary Treatment Failure

  2016cites this paper
• Mutant K-RAS Promotes Invasion and Metastasis in Pancreatic Cancer Through GTPase Signaling Pathways

  2015cites this paper
• Cyclin-Dependent Kinase 5 (CDK5) Controls Melanoma Cell Motility, Invasiveness, and Metastatic Spread—Identification of a Promising Novel therapeutic target1

  2015cites this paper
• Knockdown of PFTK1 inhibits tumor cell proliferation, invasion and epithelial-to-mesenchymal transition in pancreatic cancer.

  2015cites this paper
• Effects of altered ephrin-A5 and EphA4/EphA7 expression on tumor growth in a medulloblastoma mouse model

  2015cites this paper